RxSight Reports Decrease in Q2 Sales and Increased Operating Losses Despite Revenue Growth in First Half of 2025

RxSight, Inc. reported its financial results for the second quarter of 2025, revealing a decrease in sales and an increase in operating losses compared to the same period in 2024. The company generated $33.6 million in revenue for the three months ended June 30, 2025, a decline of 3.6% from $34.9 million in the prior year. For the first half of 2025, total sales increased by 11.1% to $71.5 million, up from $64.4 million in the same period of 2024. Despite the overall revenue growth for the six-month period, the company experienced a net loss of $11.8 million for the second quarter, a significant increase from the $6.1 million loss reported in the same quarter last year.

The company's operating expenses rose sharply, with selling, general, and administrative expenses increasing by 19.3% to $29.0 million in the second quarter, driven by higher personnel costs and stock-based compensation. Research and development expenses also grew by 23.2% to $10.2 million, reflecting increased investment in product development and clinical studies. As a result, the loss from operations for the second quarter was $14.0 million, compared to $8.3 million in the same quarter of 2024. The company’s accumulated deficit reached $642.1 million as of June 30, 2025.

Operationally, RxSight reported a decrease in the number of Light Delivery Devices (LDDs) sold, with only 40 units sold in the second quarter of 2025, down from 78 units in the same period last year. This decline was attributed to slower adoption of the RxSight technology among practices and broader economic uncertainties. However, the company noted a 13% increase in Light Adjustable Lens (LAL) sales, which totaled 27,006 units in the second quarter, up from 23,828 units in the prior year. The installed base of LDDs increased to 1,084 as of June 30, 2025, compared to 810 a year earlier.

Looking ahead, RxSight remains optimistic about its growth prospects, emphasizing plans to expand its sales organization and customer base. The company believes that its current cash and short-term investments, totaling $227.5 million, will be sufficient to fund operations for at least the next 12 months. RxSight intends to continue investing in its sales and marketing efforts, as well as in research and development to enhance its product offerings and improve clinical outcomes. The company is also exploring opportunities for geographic expansion and potential acquisitions to strengthen its market position in the premium intraocular lens segment.